3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
59
Recruiting
25
Terminated
24
Active not recruiting
14
Withdrawn
8
Unknown
7
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
2
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Breast Neoplasms
430
Neoplasms
284
Carcinoma, Non-Small-Cell Lung
266
Colorectal Neoplasms
228
Lung Neoplasms
173
Prostatic Neoplasms
171
Carcinoma, Hepatocellular
156
Stomach Neoplasms
129
Leukemia, Myeloid, Acute
118
Pancreatic Neoplasms
115
Multiple Myeloma
105
Recurrence
96
Uterine Cervical Neoplasms
91
Squamous Cell Carcinoma of Head and Neck
88
Neoplasm Metastasis
87
Rectal Neoplasms
85
Ovarian Neoplasms
77
Triple Negative Breast Neoplasms
75
Small Cell Lung Carcinoma
72
Head and Neck Neoplasms
68
Brain Neoplasms
68
Esophageal Neoplasms
64
Glioblastoma
63
Colonic Neoplasms
60
Endometrial Neoplasms
58
Melanoma
54
Hematologic Neoplasms
53
Motor Activity
50
Precursor Cell Lymphoblastic Leukemia-Lymphoma
48
Nasopharyngeal Carcinoma
46
Interventions
trametinib
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Interventional
×
Lymphoproliferative Disorders
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled